IP Library Granted Patent US 8,383,130
Granted Patent B2
US 8,383,130 · App. 12/922,084 · Granted Feb 26, 2013

Partial peptide of lacritin

Inventors: Takeshi Nakajima (Hyogo, JP); Mitsuyoshi Azuma (Hyogo, JP)
Assignee: Senju Pharmaceutical Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,383,130
App. No.
12/922,084
Granted
Feb 26, 2013
Kind
B2
Abstract

The invention provides a polypeptide comprising the amino acid sequence of SEQ ID NO: 1, which is a particular partial sequence of lacritin, and having an amino acid length of not more than 70 residues. The polypeptide of the invention can promote adhesion between a cell and an extracellular matrix, and can promote tear fluid secretion from lacrimal gland acinar cells.

Claims (21)

1. An isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 1 and having an amino acid length of not more than 70 residues.

2. A pharmaceutical product comprising the polypeptide of claim 1 .

3. A method of promoting corneal epithelial cell adhesion, which method comprises contacting a corneal epithelial cell with an effective concentration of the polypeptide of claim 1 , thereby promoting adhesion of the corneal epithelial cell.

4. The polypeptide according to claim 1 , wherein the polypeptide comprises a partial sequence of the amino acid sequence of SEQ ID NO: 2.

5. A pharmaceutical product comprising the polypeptide of claim 4 .

6. A method of promoting corneal epithelial cell adhesion, which method comprises contacting a corneal epithelial cell with an effective concentration of the polypeptide of claim 4 , thereby promoting adhesion of the corneal epithelial cell.

7. The polypeptide according to claim 1 , wherein the polypeptide consists of a partial sequence of the amino acid sequence of SEQ ID NO: 2.

8. A pharmaceutical product comprising the polypeptide of claim 7 .

9. A method of promoting corneal epithelial cell adhesion, which method comprises contacting a corneal epithelial cell with an effective concentration of the polypeptide of claim 7 , thereby promoting adhesion of the corneal epithelial cell.

10. An isolated polypeptide consisting of the amino acid sequence of any of SEQ ID NOs: 3-5.

11. A pharmaceutical product comprising the polypeptide of claim 10 .

12. A method of promoting corneal epithelial cell adhesion, which method comprises contacting a corneal epithelial cell with an effective concentration of the polypeptide of claim 10 , thereby promoting adhesion of the corneal epithelial cell.

13. The polypeptide of claim 10 consisting of the amino acid sequence of SEQ ID NO: 3.

14. A pharmaceutical product comprising the polypeptide of claim 13 .

15. A method of promoting corneal epithelial cell adhesion, which method comprises contacting a corneal epithelial cell with an effective concentration of the polypeptide of claim 13 , thereby promoting adhesion of the corneal epithelial cell.

16. The polypeptide of claim 10 consisting of the amino acid sequence of SEQ ID NO: 4.

17. A pharmaceutical product comprising the polypeptide of claim 16 .

18. A method of promoting corneal epithelial cell adhesion, which method comprises contacting a corneal epithelial cell with an effective concentration of the polypeptide of claim 16 , thereby promoting adhesion of the corneal epithelial cell.

19. The polypeptide of claim 10 consisting of the amino acid sequence of SEQ ID NO: 5.

20. A pharmaceutical product comprising the polypeptide of claim 19 .

21. A method of promoting corneal epithelial cell adhesion, which method comprises contacting a corneal epithelial cell with an effective concentration of the polypeptide of claim 19 , thereby promoting adhesion of the corneal epithelial cell.

Assignments (2)
CHANGE OF ADDRESS Recorded Aug 24, 2018
From: SENJU PHARMACEUTICAL CO., LTD.
To: SENJU PHARMACEUTICAL CO., LTD.
Reel/Frame 046835/0350 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 30, 2010
From: NAKAJIMA, TAKESHI; AZUMA, MITSUYOSHI
To: SENJU PHARMACEUTICAL CO., LTD.
Reel/Frame 025072/0613 →
Priority Claims (1)
JP 2008-071065 · Mar 19, 2008 · national
Continuity (1)
Related Publication 20110008891A1 · Jan 13, 2011